19-month-old Indian-origin boy recovers from rare genetic disorder in Singapore
A 19-month-old Indian-origin boy in Singapore has fully recovered from a rare life-threatening genetic disorder after a stem-cell transplant, according to a media report.
Mannat Singh was diagnosed with severe combined immunodeficiency (SCID) when he was just six days old, making him highly vulnerable to even the common flu, The Straits Times newspaper reported.
Mannat, the first baby in Singapore to be diagnosed with SCID at birth, successfully underwent the stem-cell transplant in 2023 before the emergence of SCID symptoms.
Today, Mannat is healthy, the paper reported.
He had Artemis SCID, a rare form of recessive radiosensitive SCID, which meant he could not be treated with radiation or have certain scans done. Without treatment, Mannat would not have made it past his first birthday, according to the Singapore daily report.
His mother Harminder Kaur, 39, a nurse, recalled the guilt and fear she felt “because I made him this way”. “I feel life has now returned to normal and we have put the past behind us,” Kaur said.
“It did not help our state of mind when his odds were stacked against him,” said her husband Harminder Singh, 39, an IT consultant.
Mannat's condition was diagnosed at KK Women's and Children's Hospital (KKH) through the National Expanded Newborn Screening (NENS) programme.
The programme, which started in 2006 with the aim of screening all babies born in Singapore for metabolic and heritable diseases, was expanded in 2019 to include five other treatable serious childhood-onset conditions such as SCID and cystic fibrosis.
“The highest success is when it is performed within the first three to four months of life, before the baby develops significant infections. This makes SCID screening at birth crucial for early diagnosis to actively prevent infection,” the paper quoted a consultant with the rheumatology and immunology service at KKH as saying.
Unlock Exclusive Insights with The Tribune Premium
Take your experience further with Premium access.
Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Already a Member? Sign In Now